About Topas Therapeutics
Topas Therapeutics is a company based in Hamburg (Germany) founded in 2016. Topas Therapeutics has raised $67.46 million across 6 funding rounds from investors including Evotec, Gimv and European Union. The company has 14 employees as of December 31, 2020. Topas Therapeutics operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter Hamburg, Germany
- Employees 14 as on 31 Dec, 2020
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$67.46 M (USD)
in 6 rounds
-
Latest Funding Round
$21.27 M (USD), Series B
Jul 29, 2021
-
Investors
Evotec
& 7 more
-
Employee Count
14
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Topas Therapeutics
Unlock access to complete
Funding Insights of Topas Therapeutics
Topas Therapeutics has successfully raised a total of $67.46M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $21.27 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Topas Therapeutics
Topas Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Evotec, Gimv and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A European life sciences venture capital investor is operated.
|
Locked | Locked | Locked | |
|
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe
|
Locked | Locked | Locked | |
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Locked | Locked | Locked |
Investor details for Topas Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Topas Therapeutics
Investment portfolio details for Topas Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Topas Therapeutics
Detailed financials for Topas Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Topas Therapeutics Comparisons
Peer comparison for Topas Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Topas Therapeutics
Topas Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Topas Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Topas Therapeutics
Complete news archive for Topas Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Topas Therapeutics
Topas Therapeutics was founded in 2016.
Topas Therapeutics is headquartered in Hamburg, Germany. It is registered at Hamburg, Hamburg, Germany.
Topas Therapeutics is a funded company, having raised a total of $67.46M across 6 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Topas Therapeutics is 14.
Founded in 2016 and based in Hamburg, Germany, nanoparticle-based therapeutics targeting immunology disorders are developed. Operations focus on the biotech sector, with a pipeline that includes TPM 203 for pemphigus vulgaris, TPM 501502 for celiac disease, and interventions for anti-drug immune responses. Research and development activities are centered on advancing these candidates toward clinical applications in immune-related conditions.
Topas Therapeutics's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
Topas Therapeutics has 8 investors. Key investors include Evotec, Gimv, European Union, Vesalius Biocapital, and BioMedPartners.